Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment

被引:1
作者
Tong, Ling-Wu [1 ]
Hu, Yong-Shan [1 ]
Yu, Shi-Jing [1 ]
Li, Cheng-Lei [1 ]
Shao, Jing-Wei [1 ]
机构
[1] Fuzhou Univ, Coll Chem, Fujian Prov Key Lab Canc Metastasis Chemoprevent &, Fuzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
CRISPR/Cas9; liver cancer; immune checkpoint; immunotherapy; ADVANCED HEPATOCELLULAR-CARCINOMA; UP-REGULATION; OPEN-LABEL; PHASE-III; T-CELLS; RNA; CRISPR-CAS9; BACTERIA; PEMBROLIZUMAB; BLOCKADE;
D O I
10.1088/1361-6528/ad5f33
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Liver cancer, which is well-known to us as one of human most prevalent malignancies across the globe, poses a significant risk to live condition and life safety of individuals in every region of the planet. It has been shown that immune checkpoint treatment may enhance survival benefits and make a significant contribution to patient prognosis, which makes it a promising and popular therapeutic option for treating liver cancer at the current time. However, there are only a very few numbers of patients who can benefit from the treatment and there also exist adverse events such as toxic effects and so on, which is still required further research and discussion. Fortunately, the clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9 (CRISPR/Cas9) provides a potential strategy for immunotherapy and immune checkpoint therapy of liver cancer. In this review, we focus on elucidating the fundamentals of the recently developed CRISPR/Cas9 technology as well as the present-day landscape of immune checkpoint treatment which pertains to liver cancer. What's more, we aim to explore the molecular mechanism of immune checkpoint treatment in liver cancer based on CRISPR/Cas9 technology. At last, its encouraging and powerful potential in the future application of the clinic is discussed, along with the issues that already exist and the difficulties that must be overcome. To sum up, our ultimate goal is to create a fresh knowledge that we can utilize this new CRISPR/Cas9 technology for the current popular immune checkpoint therapy to overcome the treatment issues of liver cancer.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Efficient gene editing in Corynebacterium glutamicum using the CRISPR/Cas9 system
    Peng, Feng
    Wang, Xinyue
    Sun, Yang
    Dong, Guibin
    Yang, Yankun
    Liu, Xiuxia
    Bai, Zhonghu
    MICROBIAL CELL FACTORIES, 2017, 16
  • [42] Genome editing system CRISPR/CAS9 and peculiarities of its application in monocots
    Gerasimova, S. V.
    Khlestkina, E. K.
    Kochetov, A. V.
    Shumny, V. K.
    RUSSIAN JOURNAL OF PLANT PHYSIOLOGY, 2017, 64 (02) : 141 - 155
  • [43] Development and application of a CRISPR/Cas9 system for Bacillus licheniformis genome editing
    Zhou, Cuixia
    Liu, Huan
    Yuan, Feiyan
    Chai, Haonan
    Wang, Haikuan
    Liu, Fufeng
    Li, Yu
    Zhang, Huitu
    Lu, Fuping
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2019, 122 : 329 - 337
  • [44] Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
    Raquel Rodriguez-Rodriguez, Diana
    Ramirez-Solis, Ramiro
    Alberto Garza-Elizondo, Mario
    De Lourdes Garza-Rodriguez, Maria
    Alberto Barrera-Saldana, Hugo
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 43 (04) : 1559 - 1574
  • [45] Application of CRISPR/Cas9 Gene Editing System on MDV-1 Genome for the Study of Gene Function
    Zhang, Yaoyao
    Tang, Na
    Sadigh, Yashar
    Baigent, Susan
    Shen, Zhiqiang
    Nair, Venugopal
    Yao, Yongxiu
    VIRUSES-BASEL, 2018, 10 (06):
  • [46] CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
    Ma, Linyuan
    Jang, Lydia
    Chen, Jian
    Song, Jun
    Yang, Dongshan
    Zhang, Jifeng
    Chen, Y. Eugene
    Xu, Jie
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (148):
  • [47] Genome editing system CRISPR/CAS9 and peculiarities of its application in monocots
    S. V. Gerasimova
    E. K. Khlestkina
    A. V. Kochetov
    V. K. Shumny
    Russian Journal of Plant Physiology, 2017, 64 : 141 - 155
  • [48] ATM and ATR gene editing mediated by CRISPR/Cas9 in Chinese Hamster cells
    Maeda, Junko
    Chailapakul, Piyawan
    Kato, Takamitsu A.
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2024, 829 : 111871
  • [49] Potential therapeutic strategies for osteoarthritis via CRISPR/Cas9 mediated gene editing
    Vlashi, Rexhina
    Zhang, Xingen
    Li, Haibo
    Chen, Guiqian
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2024, 25 (02) : 339 - 367
  • [50] Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
    Singh, Kshitiz
    Evens, Hanneke
    Nair, Nisha
    Rincon, Melvin Y.
    Sarcar, Shilpita
    Samara-Kuko, Ermira
    Chuah, Marinee K.
    VandenDriessche, Thierry
    MOLECULAR THERAPY, 2018, 26 (05) : 1241 - 1254